Symposium 1: MIS Beyond the Bunion 
Moderators:  Christopher P. Miller, MD, MHS, and Rebecca A. Cerrato, MD 

Symposium 2: Kenneth A. Johnson Symposium on Controversies in Foot and Ankle Surgery
Moderators:  Michael S. Aronow, MD, and David B. Thordarson, MD 

Symposium 3: AVN of the Foot and Ankle: Where Did the Flow Go? 
Moderators:  Thomas G. Harris, MD, and Xin Ma, MD 

Symposium 4: Unleashing the Potential of Emerging Movement Assessment Technologies from the Lab to the “Field” (Research Forum) 
Moderators: Jason T. Bariteau, MD

Symposium 5: Practice Efficiency 
Moderators: Max P. Michalski, MD, and Michael C. Greaser, MD 

Symposium 6: TAR: Intraoperative Strategies 
Moderators:  Casey J. Humbyrd, MD, MBE, and Kristian Buedts, MD 

Symposium 7: Hindfoot Trauma 
Moderators: Bruce J. Sangeorzan, MD, and Michael S. Aronow, MD 

Symposium 8: Sports Injuries of the Forefoot and Midfoot 
Moderators:  Mark C. Drakos, MD, and Marissa D. Jamieson, MD 

Symposium 9: Flatfoot, PCFD... or Whatever We Call It These Days 
Moderators:  Scott J. Ellis, MD, and Simon R. Platt, MBChB, FRCS 

Symposium 10: Wounds and Woes 
Moderator:  Alastair S.E. Younger, MBChB, ChM, and Amanda J. Fantry, MD 

Symposium 11: The Painful Total Ankle 
Moderator:  Mark E. Easley, MD, and Sara Lyn Miniaci-Coxhead, MD 

Paper Session 1A: Minimally Invasive Surgery 
Moderators:  Peter G. Mangone, MD, and Gary W. Stewart, MD 

Paper Session 1B: CHORD 
Moderators: Kenneth J. Hunt, MD 

Paper Session 2A: Total Ankle Replacement Part 1 
Moderators:  David I. Pedowitz, MD, MS, and Mark P. Slovenkai, MD 

Paper Session 2B: Forefoot 
Moderators:  John T. Campbell, MD, and Paul G. Talusan, MD 

Paper Session 3A: Sports
Moderators:  John T. Campbell, MD, and Paul G. Talusan, MD 

Paper Session 3B: Trauma
Moderators: John Y. Kwon, MD, and Matthew S. Conti, MD 

Paper Session 4A: Hindfoot/Midfoot
Moderators:  Andrew P. Thome Jr., MD, and Marc D. Chodos, MD 

Paper Session 4B: Miscellaneous
Moderators:  Jeannie Huh, MD 

Paper Session 5A: Total Ankle Replacement Part 2 
Moderators:  Jeremy J. McCormick, MD, and Xu Wang, MD 

Paper Session 5B: Diabetes/Charcot 
Moderators:  Michael S. Pinzur, MD, and Amgad M. Haleem Amin, MD, PhD 

Accreditation

The American Orthopaedic Foot & Ankle Society (AOFAS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

Credit Designation Statement

The AOFAS designates this enduring activity for a maximum of 21.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Need

A need for this educational activity has been determined based on previous course evaluations and the AOFAS educational curriculum. The content of this course was based on current issues and topics provided by AOFAS membership and leadership. For more information on the AOFAS CME mission, visit aofas.org/education.

Accreditation

The American Orthopaedic Foot & Ankle Society (AOFAS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

Disclaimer

The material presented in this continuing medical education activity has been made available by the American Orthopaedic Foot & Ankle Society (AOFAS) for educational purposes only. This material is not intended to represent the only, nor necessarily the best, methods or procedures appropriate for the medical situation discussed, but rather is intended to present an approach, view, statement, or opinion of the authors or presenters, which may be helpful or of interest to other practitioners. Methods, techniques, and procedures demonstrated and views and opinions expressed by speakers, presenters, and faculty are their own, and do not necessarily represent those of AOFAS, nor does presentation on the program represent or constitute endorsement or promotion by AOFAS. AOFAS expressly disclaims any warranties or guarantees, expressed or implied, and shall not be liable for damages of any kind in connection with the material, methods, information, techniques, opinions, or procedures expressed, presented, or demonstrated.

Disclosure of Conflict of Interest

Disclosure Statement
AOFAS mandates all instructors, planners, and other individuals in a position to control or influence the content of an educational activity to disclose all financial relationships that you have had in the past 24 months with ineligible companies. An "ineligible company" is one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All identified conflicts must be mitigated, and the education content vetted by the AOFAS for fair balance, scientific objectivity, and appropriateness. All disclosures will be provided in this final program distributed at the meeting to all program participants.

FDA Statement
Some drugs or medical devices demonstrated at this meeting have not been cleared by the FDA or have been cleared by the FDA for specific purposes only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or medical devices he or she wishes to use in clinical practice. AOFAS policy provides that "off label" uses of a drug or medical device may be described in its CME activities so long as the "off label" use of the drug or medical device is also specifically disclosed (i.e., it must be disclosed that the FDA has not cleared the drug or device for the described purpose). Any drug or medical device is being used "off label" if the described use is not set forth on the products approval label.

Faculty/Planner Disclosure Declaration
As an Accreditation Council for Continuing Medical Education (ACCME) provider, AOFAS has the obligation to ensure the delivery of education that is balanced and free of commercial bias. To achieve this, it is the policy of the AOFAS that all CME-related Board, committee members ("planners"), faculty, and appropriate staff disclose in writing to the learners all financial relationships that you have had in the past 24 months with ineligible companies. An "ineligible company" is one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

In addition to faculty members, commentators from the floor are charged with verbally disclosing any interests immediately prior to speaking. All disclosures are provided in this final program distributed at the meeting to all program participants.

In accordance with AOFAS policy:
Faculty participation in this educational activity will be predicated upon timely submission and review of AOFAS disclosure. An individual who refuses to disclose relevant financial relationships will be disqualified from being a planning committee member, a teacher, or an author of CME, and cannot have control of, or responsibility for, the development, management, presentation, or evaluation of the CME activity. Non-compliance will result in a faculty member being stricken from the program.

An indication of the participant's disclosure appears after his or her name as well as the commercial company or institution that provided the support. AOFAS does not view the existence of these disclosed interests or commitments as necessarily implying bias or decreasing the value of the author's participation in this activity. In addition to ensuring that presentations be free of bias, faculty members are required to ensure that all material presented and discussed will be based on best-available evidence.